Q4 Earnings Forecast for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Research analysts at Leerink Partnrs reduced their Q4 2025 earnings per share estimates for shares of Illumina in a report released on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now anticipates that the life sciences company will post earnings of $1.24 per share for the quarter, down from their previous forecast of $1.25. The consensus estimate for Illumina’s current full-year earnings is $4.11 per share. Leerink Partnrs also issued estimates for Illumina’s FY2026 earnings at $4.90 EPS.

Other equities analysts also recently issued reports about the stock. Robert W. Baird lifted their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. UBS Group lifted their price target on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Piper Sandler lowered their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. TD Cowen raised their target price on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Finally, Stephens upped their price target on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $165.95.

Illumina Stock Up 0.4 %

NASDAQ ILMN opened at $139.68 on Wednesday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina has a 52 week low of $100.08 and a 52 week high of $156.66. The business’s fifty day simple moving average is $141.46 and its 200-day simple moving average is $132.03. The firm has a market cap of $22.15 billion, a PE ratio of -14.02 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm’s revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.33 earnings per share.

Institutional Investors Weigh In On Illumina

A number of hedge funds have recently added to or reduced their stakes in ILMN. Victory Capital Management Inc. raised its stake in shares of Illumina by 5.9% in the second quarter. Victory Capital Management Inc. now owns 134,094 shares of the life sciences company’s stock valued at $13,997,000 after acquiring an additional 7,527 shares in the last quarter. Private Advisor Group LLC raised its position in Illumina by 122.5% in the 2nd quarter. Private Advisor Group LLC now owns 11,025 shares of the life sciences company’s stock valued at $1,152,000 after purchasing an additional 6,070 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Illumina during the second quarter worth about $466,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Illumina during the second quarter worth approximately $109,000. Finally, Choreo LLC acquired a new stake in Illumina in the second quarter valued at approximately $503,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.